|
Living Medical Textbook From Projects In Knowledge |
|
|
Chapter 1 Overview of Osteoporosis Last Reviewed: May 20, 2010 |
||
|
Chapter 2 Identifying Patients at Risk for Osteoporosis and Fractures Last Reviewed: May 20, 2010 |
||
|
Chapter 3 Assessment of Fracture Risk Using FRAX® Last Reviewed: May 20, 2010 |
||
|
Chapter 4 Treatment of Osteoporosis Last Reviewed: May 20, 2010 |
||
|
Chapter 5 Management of the Postfracture Patient Last Reviewed: May 20, 2010 |
||
|
Chapter 6 Monitoring Last Reviewed: May 20, 2010 |
||
|
| Table of Contents |
|
Chapter 6 - Monitoring |
|
Patients may not respond to osteoporosis therapy for a variety of reasons, including poor adherence and undiagnosed secondary medical conditions. Monitoring enables the clinician to identify those patients who are continuing to lose bone mass while on therapy and address the factors compromising response. In this chapter, Dr. E. Michael Lewiecki describes the rationale and specifics of effective monitoring.  top |
| |
|
Chapter 5 - Management of the Postfracture Patient |
|
Join Dr. Cheryl L. Lambing for Chapter 5 of the Osteoporosis Living Medical Textbook™ as she outlines postfracture management for patients with osteoporosis-related fractures. Whether of the wrist, hip, or spine, all fractures represent an increased risk for disability and future fracture. Know the steps of the recovery process for your patients with fractures: acute treatment, medical evaluation, and rehabilitation. top |
| |
|
Chapter 4 - Treatment of Osteoporosis |
|
Effective osteoporosis treatment plans include a bone-active agent as well as a number of nutritional, environmental, and lifestyle modifications. Together, these pharmacologic and nonpharmacologic interventions help to build or maintain bone mass and prevent fracture. Join Drs. Paul D. Miller and Jeri W. Nieves for chapter 4 of the Osteoporosis Living Medical Textbook™ as they survey the pharmacologic and nonpharmacologic intervention options to assist clinicians in individualizing treatment plans uniquely suited to the needs of each patient. top |
| |
|
Chapter 3 - Assessment of Fracture Risk Using FRAX® |
|
FRAX® is a new web-based tool designed by the World Health Organization to help clinicians worldwide accurately estimate fracture risk in their patients with osteopenia, or low bone mass. The tool, while a powerful statistical predictor, is not without limitations and caveats, however. Join Dr. Marjorie M. Luckey in the written chapter and audio podcast discussion as she guides you through the use of FRAX in clinical practice. top |
| |
|
Chapter 2 - Identifying Patients at Risk for Osteoporosis and Fractures |
|
Which patients in your practice are at risk for osteoporosis and fracture? Dr. Marjorie M. Luckey helps you recognize risk factors that go beyond postmenopausal status and age. Use tools already at hand—medical history, physical examination, and laboratory testing—to uncover potential secondary causes of osteoporosis. Determine which patients need bone mineral density testing, and interpret dual energy X-ray absorptiometry (DXA) results with confidence. top |
| |
|
Chapter 1 - Overview of Osteoporosis |
|
After reviewing the epidemiology of osteoporosis and its associated disease burden, Dr. E. Michael Lewiecki summarizes the physiology of bone remodeling to lay a foundation for understanding the role of current and emerging therapies. In this six-part web-based reference tool, noted experts present up-to-date information about this serious—and growing—health concern. This is part of the Osteoporosis Compendium. top |
| |
|
| CME INFORMATION |
ACTIVITY GOAL |
The goal of this CME/CE activity is to address gaps in competence and practice performance by:
|
TARGET AUDIENCE |
| This activity is designed for primary care physicians, including internists, family practitioners, gynecologists, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures. |
LEARNING OBJECTIVES |
|
| top1892 |
|
|||
|
|||
|
|||
|
This activity is supported by an educational donation provided by Amgen.
|
|||
| EDITORIAL BOARD | |||
| CONTRIBUTING EDITOR Cheryl L. Lambing, MD |
|||
|
|||
| CONTRIBUTING EDITOR E. Michael Lewiecki, MD, FACP, FACE |
|||
|
|||
| CONTRIBUTING EDITOR Marjorie M. Luckey, MD |
|||
|
|||
| CONTRIBUTING EDITOR Paul D. Miller, MD |
|||
|
|||
| CONTRIBUTING EDITOR Jeri W. Nieves, PhD |
|||
|
|||
